Antibiotics

No difference was observed in any of the outcomes and there was no impact on the duration of therapy.

GDC and DSENS were both seen to be safe and effective tools to optimize therapy in the study participants.

An effort to increase stewardship showed that 5-day and 10-day prescription stop dates for antibiotics did little to influence actual therapy length and outcomes.

An assessment from the Cleveland Clinic shows prescribing concordant to guidelines can exceed 60% in certain facilities.

Almost half of the participants in the study had an opportunity to improve their antibiotic regimen.

The pilot program was demonstrated to significantly reduce days of antibiotic therapy.

More than half of the pharmacist led interventions were accepted by providers during the intervention period.

Interventions implemented by pharmacists were more likely to be accepted by prescribers.

Short-course antibiotics are preferable for certain common bacterial infections, including acute bronchitis, pneumonia, urinary tract infection and cellulitis, the American College of Physicians said in a report issuing practice advice.

A study of more than 400 hospitals offers takeaways for creating antibiotic stewardship programs in hospitals around the country.

Escalating usage and more drug choices are putting more people at risk.

This approach can help with clinical outcomes and mortality, but resistance is not as well defined.

Ongoing education and proven outcomes need to aid this form of testing.

Social identity plays an important role in how antimicrobial stewards see their roles and influences how they communicated with prescribers.

Letters to legislators call for increased funding to address ongoing crisis.

Spero Therapeutics expects to submit a new drug application this year for Tebipenem HBr, the first oral carbapenem for treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).

Filmmaker Bill Mudge has released his new documentary, Beating Superbugs: Can We Win? It looks at emerging technologies designed to develop new therapies to combat antibiotic resistance (ABR).

New drugs likely won’t meet resistance challenges ahead, authors say.

Melinta Therapeutics’ oritavancin therapy is indicated for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

While the world’s focus remains on COVID-19, beyond this ongoing crisis lingers another that requires leadership, innovation, and collaboration from policy makers, the health care community, and the private sector.

A pair of experts assess literature on the means of interpreting hospitalized patient antibiotic resistance through machine learning.

An assessment of a comparative study between leading options for a burdensome infection.

The IDSA representative discusses advances made in recent years, and how foundational guidance could be set by the FDA with input from specialists.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

As the threat of infection with multidrug-resistant gram-negative organisms persists, new antimicrobials are a welcome addition to the armamentarium of infectious diseases clinicians.

Why it may be more prudent for prescribing clinicians to assume viral, rather than bacterial, infection while awaiting test results in presenting pediatric cases.

New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.